MAPT and Alzheimer disease: Early trials are evolving along these lines, however, and there is hope that these early-detection tools will allow enrichment of trials with early AD patients with the potential to benefit from anti-tau antibodies or other novel therapies prior to the onset of irreversible cognitive decline.